Pharmaceutical intermediates
Linagliptin Intermediates
6 pharmaceutical intermediates for Linagliptin. Indication: Diabetes Mellitus, Type 2.
About Linagliptin
- Originator
- Boehringer Ingelheim International Gmbh
- Indication
- Diabetes Mellitus, Type 2
- Approved Date
- 01/30/2015
- DS/DP
- 05/02/2025
Available intermediates
6 intermediates currently listed for Linagliptin. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Methylxanthine | 1076-22-8 | / | / |
| 8-Bromo-3-methyl-3,9-dihydro-1H-purine-2,6-dione | 93703-24-3 | / | / |
| 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-3,7-dihydro-1H-purine-2,6-dione | 666816-98-4 | / | / |
| 2-(Chloromethyl)-4-methylquinazoline | 109113-72-6 | / | / |
| 8-Bromo-7-(but-2-yn-1-yl)-3-methy1-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione | 853029-57-9 | / | / |
| [(3R)-1-[7-(2-Butynyl)-2,3,6,7-tetrahydro-3-methy1-1-[(4-methy1-2-quinazolinyl)methyl]-2,6-dioxo-1H-purin-8-yll-3-piperidinyllcarbamicacid 1,1-dimethylethyl ester | 668273-75-4 | / | / |
Building toward Linagliptin?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →